Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Asthma and mast cell activation.

M Kaliner1

  • 1Allergic Diseases Section, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.

The Journal of Allergy and Clinical Immunology
|February 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allergic diseases in the new millennium. Introduction.

Postgraduate medicine·2009
Same author

Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).

Vox sanguinis·2003
Same author

Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2000
Same author

Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses.

The Journal of allergy and clinical immunology·1999
Same author

Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders.

The Journal of allergy and clinical immunology·1999
Same author

Treatment of sinusitis in the next millennium.

Allergy and asthma proceedings·1998
Same journal

Tamoxifen-driven neutrophil reprogramming protects from pulmonary Granulibacter bethesdensis infection in chronic granulomatous disease.

The Journal of allergy and clinical immunology·2026
Same journal

Clinical and transcriptomic characterization of mixed granulocytic COPD phenotype.

The Journal of allergy and clinical immunology·2026
Same journal

Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSION.

The Journal of allergy and clinical immunology·2026
Same journal

Maternal antibiotic exposure alters the newborn metabolomic profile and increases the risk of respiratory infections in offspring: a 13-year longitudinal birth cohort study.

The Journal of allergy and clinical immunology·2026
Same journal

Selective Elimination of Mast Cells via Siglec-6-Targeted Nanodelivery of Drug Payload.

The Journal of allergy and clinical immunology·2026
Same journal

Loss of epidermal miR-149 sensitizes to skin inflammation.

The Journal of allergy and clinical immunology·2026
See all related articles

Mast cell activation (MCA) in asthma releases mediators causing airway inflammation and vascular permeability. Understanding these processes, including substance P

Area of Science:

  • Immunology
  • Pulmonology
  • Pathophysiology

Background:

  • Allergens trigger IgE-mediated mast cell degranulation in the lungs.
  • This process releases mediators, leading to airway inflammation and characteristic asthma pathology.
  • Vascular permeability is a key, often overlooked, feature of mast cell degranulation in asthma.

Purpose of the Study:

  • To elucidate the role of mast cell activation (MCA) in asthma pathophysiology.
  • To highlight the significance of vascular permeability as a hallmark of MCA.
  • To explore the connection between MCA, substance P release, and vasodilation.

Main Methods:

  • Review of existing literature on mast cell activation and asthma.
  • Analysis of the mechanisms linking antigen challenge to mediator release.

Related Experiment Videos

  • Examination of studies involving antidromic nerve stimulation and substance P.

    • Main Results:

    • Mast cell degranulation releases mediators that cause bronchospasm, edema, and hyperreactivity.
    • Vascular permeability is a rapid response to antigen challenge, akin to muscle contraction.
    • Antidromic nerve stimulation suggests a link between MCA and histamine-induced substance P release, causing vasodilation.

    Conclusions:

    • Understanding the pathophysiologic events of MCA is crucial for asthma therapy development.
    • Targeting mast cell mediators and pathways like substance P may offer therapeutic benefits.
    • Further research into the late allergic response, involving histamine-releasing factors and MCA recrudescence, is warranted.